Table 1.
Inhibitors of the Ubiquitin Proteasome System in Clinical Development.
| Target | Inhibitor | Cancer Type | Clinical Stage | Reference/ Trial ID |
|---|---|---|---|---|
| 20S Proteasome (Beta-5 subunit) | Bortezomib | MM, MCL | Approved | [93,94] |
| Carfilzomib | MM | Approved | [95] | |
| Ixazomib | MM | Approved | [96] | |
| Oprozomib | MM | Phase Ib/II | [97] | |
| Marizomib | MM | Phase I | [98] | |
| DIPG | Phase I | NCT04341311 | ||
| MDM2 | Idasanutlin | Glioblastoma | Phase III | NCT03345095 |
| Breast Cancer | Phase I/II | NCT03566485 | ||
| AML/ALL | Phase I/II | NCT04029688 | ||
| AMG-232 | Sarcoma | Phase Ib | NCT03217266 | |
| Lymphoma | Phase I | NCT04502394 | ||
| MM | Phase I | NCT03031730 | ||
| AML | Phase Ib | NCT04190550 | ||
| HDM201 | CRC | Phase I | NCT03714955 | |
| APG-115 | AML | Phase Ib | NCT04275518 | |
| CRL | MLN4924 (Pevonedistat) | MM | Phase I | NCT03770260 |
| AML | Phase Ib | NCT01814826 | ||
| AML | Phase I/II | NCT03862157 | ||
| AML/MDS | Phase I | NCT03772925 | ||
| NSCLC | Phase II | NCT03965689 | ||
| Lymphoma | Phase I | NCT03323034 | ||
| ALL/NHL | Phase I | NCT03349281 |
MM: Multiple Myeloma; MCL: Mantle Cell Lymphoma; DPIG: Diffuse Intrinsic Pentine Glioma; AML: Acute Myeloid Leukaemia; ALL: Acute Lymphocytic Leukaemia; CRC: Colorectal Cancer; MDS: Myelodysplastic Syndrome; NSCLC: Non-Small Cell Lung Carcinoma; NHL: Non-Hodgkin’s Lymphoma.